WONOEP appraisal: Biomarkers of epilepsy-associated comorbidities.
WONOEP appraisal: Biomarkers of epilepsy-associated comorbidities.
复制标题
DOI：
10.1111/epi.13652
复制
发表时间：
2017-03
期刊：
影响因子：
5.6
通讯作者：
Friedman A
中科院分区：
文献类型：
--
作者：
Ravizza T;Onat FY;Brooks-Kayal AR;Depaulis A;Galanopoulou AS;Mazarati A;Numis AL;Sankar R;Friedman A
神经和精神合并症在癫痫患者中很常见。此类合并症的诊断、预测和药效学生物标志物尚不存在。它们可能与癫痫发生/发作具有相同的发病机制，因此是未满足的临床需求。第十三届癫痫神经生物学研讨会 (WONOEP) 共病生物标志物小组的目标是展示该领域最先进的最新研究成果，强调癫痫共病的潜在生物标志物。我们回顾了该领域的最新进展，包括 2015 年 8 月 31 日至 9 月 4 日在海贝利亚达岛（土耳其伊斯坦布尔）举行的 WONOEP 会议上讨论的共病的分子、影像和遗传生物标志物。我们进一步强调了合并症研究的新方向和概念以及用于预测、诊断和治疗癫痫相关合并症的潜在新生物标志物。各种分子信号通路的激活，例如“Janus 激酶/信号转导器和转录激活器”、“雷帕霉素的哺乳动物靶标”和氧化应激，已被证明与随后认知异常的存在和严重程度相关。此外，血清素能传递功能障碍、下丘脑-垂体-肾上腺皮质轴的过度活跃、炎症细胞因子的作用以及遗传因素的贡献最近都被认为与理解癫痫相关的抑郁症和认知缺陷有关。最近的证据支持成像研究作为潜在生物标志物的效用。这种生物标志物的作用可能远远超出了合并症的诊断，因为积累的临床数据表明合并症可以预测癫痫的结果。未来的研究需要揭示是否可以在临床环境中检测到特定信号通路或先进成像技术的分子变化，并与癫痫相关的合并症相关。可靠的生物标志物将有助于更准确地诊断和改善癫痫相关合并症的治疗。
Neurologic and psychiatric comorbidities are common in patients with epilepsy. Diagnostic, predictive, and pharmacodynamic biomarkers of such comorbidities do not exist. They may share pathogenetic mechanisms with epileptogenesis/ictogenesis, and as such are an unmet clinical need. The objectives of the subgroup on biomarkers of comorbidities at the XIII Workshop on the Neurobiology of Epilepsy (WONOEP) were to present the state-of-the-art recent research findings in the field that highlighting potential biomarkers for comorbidities in epilepsy. We review recent progress in the field, including molecular, imaging, and genetic biomarkers of comorbidities as discussed during the WONOEP meeting on August 31–September 4, 2015, in Heybeliada Island (Istanbul, Turkey). We further highlight new directions and concepts from studies on comorbidities and potential new biomarkers for the prediction, diagnosis, and treatment of epilepsy-associated comorbidities. The activation of various molecular signaling pathways such as the “Janus Kinase/Signal Transducer and Activator of Transcription,” “mammalian Target of Rapamycin,” and oxidative stress have been shown to correlate with the presence and severity of subsequent cognitive abnormalities. Furthermore, dysfunction in serotonergic transmission, hyperactivity of the hypothalamic-pituitary-adrenocortical axis, the role of the inflammatory cytokines, and the contributions of genetic factors have all recently been regarded as relevant for understanding epilepsy-associated depression and cognitive deficits. Recent evidence supports the utility of imaging studies as potential biomarkers. The role of such biomarker may be far beyond the diagnosis of comorbidities, as accumulating clinical data indicate that comorbidities can predict epilepsy outcomes. Future research is required to reveal whether molecular changes in specific signaling pathways or advanced imaging techniques could be detected in the clinical settings and correlate with epilepsy-associated comorbidities. A reliable biomarker will allow a more accurate diagnosis and improved treatment of epilepsy-associated comorbidities.
登录
查看更多内容
影响因子：
14.5
作者：
Hermann, Bruce;Jones, Jana;Seidenberg, Michael
通讯作者：
Seidenberg, Michael
影响因子：
3.7
作者：
Brewster AL;Lugo JN;Patil VV;Lee WL;Qian Y;Vanegas F;Anderson AE
通讯作者：
Anderson AE
影响因子：
6.1
作者：
Grabenstatter HL;Del Angel YC;Carlsen J;Wempe MF;White AM;Cogswell M;Russek SJ;Brooks-Kayal AR
通讯作者：
Brooks-Kayal AR
影响因子：
9.9
作者：
Busch, R. M.;Lineweaver, T. T.;Diaz-Arrastia, R.
通讯作者：
Diaz-Arrastia, R.
影响因子：
2.6
作者：
Furtado Gouveia, Telma Luciana;Vieira de Sousa, Paula Viviane;Naffah-Mazzacoratti, Maria da Graca
通讯作者：
Naffah-Mazzacoratti, Maria da Graca